

# AIM ImmunoTech Inc.

14:58 16 May 2019

## Hemispherx Biopharma's well-funded to take promising cancer drug Ampligen through clinical trials

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) revealed Thursday that it has boosted its cash pile impressively through May to shoulder a series of trials evaluating the company's promising cancer drug Ampligen at major cancer research hospitals.

The Orlando, Florida-based biotech said stockholders participated in a rights offering to raise \$5.3 million. Therefore, as of March 31, Hemispherx had cash and cash equivalents of \$4.9 million, compared with \$1.8 million as of December 31, 2018.

READ: Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer  
 "When our management team began three years ago, Hemispherx identified four significant steps we needed to take to make our company a success," said Hemispherx CEO Thomas K Equels. "First, raise the funds necessary to produce our drug candidate, Ampligen, for use in immuno-oncology clinical trials and other programs. Second, produce adequate supplies of Ampligen to conduct such trials. Third, initiate multiple immuno-oncology clinical trials. We have now accomplished each of these steps and are using Ampligen to treat cancers in clinical trials."

Seeking big pharma partnerships  
 Equels says "now is the time" for the company to seek out big pharma partners who share the company's "excitement and enthusiasm" for the potential of Ampligen.

"We believe that success in these trials will create the environment for that goal," said Equels. "Accomplishing success in R&D is based on such progress."

Hemispherx recently announced significant progress in multiple Ampligen-plus-checkpoint-blockade immuno-oncology programs.

Multiple trials underway  
 It has been a busy spell for the company with the following trials underway:

- Initiated a 45-patient clinical study in ovarian cancer at University of Pittsburgh Medical Center combining Ampligen, cisplatin and pembrolizumab, data expected by 2021.
- Initiated a 12-patient clinical study in colorectal cancer at Roswell Park Comprehensive Cancer Center combining Ampligen, Intron A, and celecoxib, data expected by 2020.
- Initiated a six-patient clinical study in triple negative breast cancer at Roswell Park Comprehensive Cancer Center combining with Ampligen, Intron A, celecoxib and pembrolizumab, data expected by 2020.
- Extended the Early Access Program (EAP) at the Erasmus Medical Center in the Netherlands using Ampligen in the treatment of patients with pancreatic cancer. The EAP is approved by the Dutch Health Inspectorate until

**Price:** 2.41

**Market Cap:** \$78.62 m

### 1 Year Share Price Graph



### Share Information

**Code:** AIM

**Listing:** NYSE

|                |             |            |
|----------------|-------------|------------|
| <b>52 week</b> | <b>High</b> | <b>Low</b> |
|                | 7.05        | 0.39       |

**Sector:** Pharma & Biotech

**Website:** aimimmuno.com

### Company Synopsis:

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.

**action@proactiveinvestors.com**

March 9, 2020 to treat pancreatic cancer patients diagnosed with any stage of the serious disease. Patients receive Ampligen as a maintenance therapy after completing standard care.

- An additional round of comprehensive pre-clinical animal pancreatic cancer studies were initiated at the University of Nebraska to reconfirm the successful results seen in the initial animal studies.
- Received an interim report on a recurrent Ovarian Cancer Phase 1/2 study of intraperitoneal chemo-immunotherapy at University of Pittsburgh Medical Center.
- The Phase 2 study of neoadjuvant conditioning of prostate cancer using Ampligen as a component of chemokine modulation at Roswell Park Comprehensive Cancer Center has received authorization to proceed by the FDA.

Research and development manufacturing-related expenses for the first quarter were \$0.93 million, an 8% increase compared with \$0.86 million for the first quarter of 2018. The increase was due to Ampligen related stability testing and maintenance.

The net loss from continuing operations for the first quarter was \$3.36 million, or \$0.07 per share, compared with \$2.71 million, or \$0.07 per share, for the same period a year ago.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).